These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
9. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204 [TBL] [Abstract][Full Text] [Related]
10. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960 [TBL] [Abstract][Full Text] [Related]
11. Sequential treatment for recurrent localized prostate cancer. Van Der Poel HG; Moonen L; Horenblas S J Surg Oncol; 2008 Apr; 97(5):377-82. PubMed ID: 18360820 [TBL] [Abstract][Full Text] [Related]
12. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618 [TBL] [Abstract][Full Text] [Related]
13. [Adjuvant and salvage radiotherapy after radical prostatectomy]. Milecki P; Kwias Z; Skowronek J; Stachowski T Pol Merkur Lekarski; 2004 May; 16(95):495-9. PubMed ID: 15518437 [TBL] [Abstract][Full Text] [Related]
14. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
15. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience. Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484 [TBL] [Abstract][Full Text] [Related]
17. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. King CR; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668 [TBL] [Abstract][Full Text] [Related]
18. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197 [TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. Syndikus I; Pickles T; Kostashuk E; Sullivan LD J Urol; 1996 Jun; 155(6):1983-6. PubMed ID: 8618303 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]